Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. - Wikidata - awgldk - TriplyDB

Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.

Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.

http://www.wikidata.org/entity/Q38874383

about

Function and Clinical Implications of Long Non-Coding RNAs in Melanoma.Noncalcemic 20-hydroxyvitamin D3 inhibits human melanoma growth in in vitro and in vivo models Advances in Immunotherapy for Melanoma: A Comprehensive Review.On the role of classical and novel forms of vitamin D in melanoma progression and management.Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.Expression profiles analysis of long non-coding RNAs identified novel lncRNA biomarkers with predictive value in outcome of cutaneous melanoma.Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management.Immune profiling of melanoma tumors reflecting aggressiveness in a preclinical model.Transplantable Melanomas in Hamsters and Gerbils as Models for Human Melanoma. Sensitization in Melanoma Radiotherapy-From Animal Models to Clinical Trials.Frameshift events predict anti-PD-1/L1 response in head and neck cancer.

P2860

Q30313298-BFCDF2DC-CB6C-4806-A2FD-B2C3C59B8F24 Q37706071-B09AD26D-9638-429E-AC05-2B6762F7DE7F Q38636521-E988478F-7544-40E5-91F7-87B917DF7F7B Q38662850-5910100C-9216-4565-8663-0434BD85F901 Q38870282-7A8EA04A-2D05-4B66-BB60-6ED1EFE030E0 Q43451695-85AA30E3-EF50-4C1F-90DE-D2DA0AD3A57E Q48218051-D8B261F4-758E-457A-AC39-EDC2E246D66B Q51795679-E589A5A0-E295-47AC-8E6E-C865A7FE37E9 Q52929781-8E7CD923-695D-43BD-B72B-C9F25489D9D5 Q54269200-68196F1A-39F4-4507-8E73-6910162C74BD

P2860

Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.

http://www.wikidata.org/entity/Q38874383

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Molecular characterisation of ...... targeted and immune therapies.

@en

type

label

Molecular characterisation of ...... targeted and immune therapies.

@en

prefLabel

Molecular characterisation of ...... targeted and immune therapies.

@en

P1433

Q38874383-94D84F84-6A42-4063-BB5C-392424757763

P1476

Q38874383-E2B0F3FF-53C9-4E87-91D0-55421B7A22FB

P2093

Q38874383-85C80285-CFAA-4051-86D6-CCB3957C32EE

Q38874383-C6363E7F-349C-4AC3-97C2-0143CBAB67E2

P275

Q38874383-3ADED479-890F-4E0B-B093-2E8943108281

P2860

Q38874383-01A4E4C9-BA90-4260-9D2E-40EE1EB4EA38

Q38874383-032EA84C-99F6-4FA9-B601-A626933BB7E1

Q38874383-076F839E-31C1-4674-954E-CDC7A6B81025

Q38874383-09513B14-A8A6-4ABA-9B89-3172A098D64C

Q38874383-116772D7-CD2D-4250-B552-02B6A80F5754

Q38874383-1E367F7B-7E5C-48C2-BC05-A59AFAA60318

Q38874383-221E442C-FA25-4CF9-AB79-A579C65D4972

Q38874383-2690D118-924C-4F22-86E2-82647A4DFDA5

Q38874383-281C4EB5-4B7A-46E8-992E-D4236D5E24F2

Q38874383-283545D0-52EF-468E-B142-98404DB64B9E

P2888

Q38874383-7DD05F2D-36E1-42E4-98B2-3F79FBAD4CF7

P304

Q38874383-3DE37BD1-C0D8-4BAC-8364-F667CF47FE5A

P31

Q38874383-9ECDFA84-5EA6-42FF-B0AA-05ED575F7660

Q38874383-D9E82FFE-41A2-41B4-8BDA-A77CA02EBCA8

P356

Q38874383-BAB4253B-1854-420E-A375-BCD54BBF7FD5

P407

Q38874383-1870D516-ECFD-40DF-A8A4-4FB8CAF3C4FD

P433

Q38874383-1D072AB8-1106-4948-8EBA-36AC3D706325

P478

Q38874383-F4A4233B-E21C-47D2-AAF8-F4530E602EDE

P5008

Q38874383-39B4286E-D0C9-477C-9B7B-E3D39CBC82F0

P577

Q38874383-86797282-FE89-4640-8C73-3C75659BC179

Q38874383-DD826897-37F7-4C0E-B4DC-204B0622AE33

P6179

Q38874383-02644735-536A-4D5D-9052-134C055A4155

P698

Q38874383-4F4C9EE0-C856-4487-A1D7-3A8599D7934C

P921

Q38874383-CB7AB97F-4875-4387-89DB-6081E0B98D67

Q38874383-E022A8A9-33E2-4522-86CC-E2A84785AEB3

P932

Q38874383-58CEF3B9-AE41-48AC-A07F-4BCED0C43BF4

P356

P1433

British Journal of Cancer

P1476

Molecular characterisation of ...... targeted and immune therapies.

@en

P2093

Ian R Watson

http://www.w3.org/2001/XMLSchema#string

Shivshankari Rajkumar

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

P2860

A landscape of driver mutations in melanoma

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

RAF inhibitors that evade paradoxical MAPK pathway activation

Major response to imatinib mesylate in KIT-mutated melanoma.

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.

Elucidating distinct roles for NF1 in melanomagenesis

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.

Nivolumab plus ipilimumab in advanced melanoma.

P2888

P304

145-155

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2016.195

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2016-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1027545802

http://www.w3.org/2001/XMLSchema#string

P698

27336610

http://www.w3.org/2001/XMLSchema#string

P921

P932

4947706

http://www.w3.org/2001/XMLSchema#string